<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00710606</url>
  </required_header>
  <id_info>
    <org_study_id>AAAC8127</org_study_id>
    <nct_id>NCT00710606</nct_id>
  </id_info>
  <brief_title>Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing®</brief_title>
  <official_title>Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Organon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are over 60 million women of reproductive age in the U.S. and a majority of these women
      qualify as overweight or obese. Evidence suggests that there is an association between
      increased body weight and decreased contraceptive efficacy. Studies with the combined
      hormonal contraceptive patch (Evra®) and the subdermal contraceptive implant (Norplant®)
      demonstrate higher failure rates in heavier versus lighter women.

      Weight related differences in the effectiveness of NuvaRing® need further study. A single
      secondary analysis of pooled data from Phase III clinical trials of NuvaRing® noted no
      difference in pregnancy rates among women in the highest weight decile (&gt;166#) versus the
      rest of the study population using the ring. (Westhoff, 2005) The finding of no difference,
      however, was influenced by too few obese subjects in the analysis which contributed to wide
      confidence limits. Additional studies are needed to explore how well the contraceptive ring
      functions to maintain effective serum steroid concentrations to suppress ovarian activity in
      obese women.

      This investigation focused on evaluating mean serum concentrations of hormones released in
      obese and normal weight women using the NuvaRing® . This study was a prospective clinical
      trial. Normal weight women are defined as women with a BMI 19-24.9 and obese women are those
      with a BMI 30-39.9. We recruited forty adult women interested in initiating the combined
      hormonal contraceptive ring to two months of use to complete analysis of at least 34 subjects
      (17 normal weight, 17 obese). We compared mean serum concentrations of ethinyl estradiol (E2)
      and etonogestrel (ENG) along with additional markers for ovarian suppression. These markers
      included sonographic evidence of follicular development and ovulation as well as circulating
      E2 levels which strongly correlate with follicular development and endometrial proliferation
      during the second month of NuvaRing® use. Assessment of these parameters will translated to
      understanding contraceptive-mediated suppression of ovarian function in these two groups.
      Subjects also logged patterns of ring use and bleeding patterns during the study period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Serum Concentrations of Etonogestrel and Ethinyl Estradiol</measure>
    <time_frame>Measurements at Week 3 and Week 6 continuous ring use</time_frame>
    <description>Serum concentrations were obtained from thirty-seven women completed follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving a Maximum Follicle Diameter &gt; 13mm During the 3 Weeks of Follow-up</measure>
    <time_frame>continuous ring use, an average of 3 weeks</time_frame>
    <description>Follicular development was minimal in both groups, with only five women achieving a maximum follicle diameter &gt; 13mm at any time during the 3 weeks of follow-up (3 normal weight and 2 obese women).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Endometrial Proliferation</measure>
    <time_frame>Transvaginal ultrasound measurements of endometrial proliferation will be completed over continuous ring use, an average of 3 weeks</time_frame>
    <description>The mean endometrial proliferation from week 1, week 2 and week3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>1- Obese Women /Nuvaring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obese subjects (BMI 30-39.9)received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2- Normal Weight / Nuvaring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal weight subjects (BMI 19-24.9) received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NuvaRing</intervention_name>
    <description>Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.</description>
    <arm_group_label>1- Obese Women /Nuvaring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NuvaRing</intervention_name>
    <description>Normal weight subjects will also receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.</description>
    <arm_group_label>2- Normal Weight / Nuvaring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-35 yo

          -  Meet BMI requirements

          -  Weight stable

          -  English speaking

          -  Desire contraception

          -  History of regular menses with normal uterus and ovaries

          -  Medically eligible for combined hormonal contraception

          -  Tolerates phlebotomy/TVS

        Exclusion Criteria:

          -  Exclusion:

          -  Heavy smokers

          -  Users of medications that alter hormone levels
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn Westhoff, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Family Planning and Preventive Services</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gu S, Sivin I, Du M, Zhang L, Ying L, Meng F, Wu S, Wang P, Gao Y, He X, et al. Effectiveness of Norplant implants through seven years: a large-scale study in China. Contraception. 1995 Aug;52(2):99-103.</citation>
    <PMID>8536454</PMID>
  </reference>
  <reference>
    <citation>Sivin I, Lähteenmäki P, Mishell DR Jr, Alvarez F, Diaz S, Ranta S, Grozinger C, Lacarra M, Brache V, Pavez M, Nash H, Stern J. First week drug concentrations in women with levonorgestrel rod or Norplant capsule implants. Contraception. 1997 Nov;56(5):317-21.</citation>
    <PMID>9437561</PMID>
  </reference>
  <reference>
    <citation>Sivin I, Wan L, Ranta S, Alvarez F, Brache V, Mishell DR Jr, Darney P, Biswas A, Diaz S, Kiriwat O, Anant MP, Klaisle C, Pavez M, Schechter J. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants. Contraception. 2001 Jul;64(1):43-9.</citation>
    <PMID>11535213</PMID>
  </reference>
  <reference>
    <citation>Smallwood GH, Meador ML, Lenihan JP, Shangold GA, Fisher AC, Creasy GW; ORTHO EVRA/EVRA 002 Study Group. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol. 2001 Nov;98(5 Pt 1):799-805.</citation>
    <PMID>11704172</PMID>
  </reference>
  <reference>
    <citation>Westhoff, C. Higher body weight does not affect NuvaRing's efficacy. Obstet Gynecol 2005; 104: 56S.</citation>
  </reference>
  <reference>
    <citation>Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002 Feb;77(2 Suppl 2):S13-8.</citation>
    <PMID>11849631</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2008</study_first_submitted>
  <study_first_submitted_qc>July 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2008</study_first_posted>
  <results_first_submitted>August 22, 2013</results_first_submitted>
  <results_first_submitted_qc>April 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 30, 2015</results_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Carolyn L. Westhoff</investigator_full_name>
    <investigator_title>Director of Family Planning and Preventive Services Division</investigator_title>
  </responsible_party>
  <keyword>contraceptive ring</keyword>
  <keyword>obesity</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>Pharmacokinetics of the contraceptive ring in obese women.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled during the months of June-September 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Obese Subjects</title>
          <description>Obese subjects (BMI 30-39.9) received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.</description>
        </group>
        <group group_id="P2">
          <title>Normal Weight Subjects</title>
          <description>Normal weight subjects (BMI 19-24.9) received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Obese Subjects</title>
          <description>Obese subjects (BMI 30-39.9)</description>
        </group>
        <group group_id="B2">
          <title>Normal Weight Subjects</title>
          <description>Normal weight subjects (BMI 19-24.9)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.5" spread="3.2"/>
                    <measurement group_id="B2" value="26.0" spread="3.6"/>
                    <measurement group_id="B3" value="25.8" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Serum Concentrations of Etonogestrel and Ethinyl Estradiol</title>
        <description>Serum concentrations were obtained from thirty-seven women completed follow-up.</description>
        <time_frame>Measurements at Week 3 and Week 6 continuous ring use</time_frame>
        <population>17 participants in each group was planned a priori to have 80% power to identify a one standard deviation difference in the mean serum levels of the contraceptive hormones. We enrolled 40 women, 2 withdrew prior to the study cycle. We excluded one woman due to removal of the CVR during the study cycle leaving 18 normal weight and 19 obese women.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Weight</title>
            <description>Women of normal weight and obese received two contraceptive rings. During the second cycle of ring use, subject returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.</description>
          </group>
          <group group_id="O2">
            <title>Obese</title>
            <description>Women of normal weight and obese received two contraceptive rings. During the second cycle of ring use, subject returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Concentrations of Etonogestrel and Ethinyl Estradiol</title>
          <description>Serum concentrations were obtained from thirty-seven women completed follow-up.</description>
          <population>17 participants in each group was planned a priori to have 80% power to identify a one standard deviation difference in the mean serum levels of the contraceptive hormones. We enrolled 40 women, 2 withdrew prior to the study cycle. We excluded one woman due to removal of the CVR during the study cycle leaving 18 normal weight and 19 obese women.</population>
          <units>ng/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Etonogesterel (ENG) Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1275" lower_limit="1116" upper_limit="1457"/>
                    <measurement group_id="O2" value="1240" lower_limit="1041" upper_limit="1477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethinyl Estradiol (EE) Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" lower_limit="17.9" upper_limit="26.6"/>
                    <measurement group_id="O2" value="14.8" lower_limit="12.7" upper_limit="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Etonogesterel (ENG) Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1063" lower_limit="730" upper_limit="1548"/>
                    <measurement group_id="O2" value="1096" lower_limit="730" upper_limit="1646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethinyl Estradiol (EE) Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="10.1" upper_limit="25.8"/>
                    <measurement group_id="O2" value="12.5" lower_limit="8.1" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving a Maximum Follicle Diameter &gt; 13mm During the 3 Weeks of Follow-up</title>
        <description>Follicular development was minimal in both groups, with only five women achieving a maximum follicle diameter &gt; 13mm at any time during the 3 weeks of follow-up (3 normal weight and 2 obese women).</description>
        <time_frame>continuous ring use, an average of 3 weeks</time_frame>
        <population>17 participants in each group was planned a priori to have 80% power to identify a one standard deviation difference in the mean serum levels of the contraceptive hormones. We enrolled 40 women, 2 withdrew prior to the study cycle. We excluded one woman due to removal of the CVR during the study cycle leaving 18 normal weight and 19 obese women.</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Subjects</title>
            <description>Obese subjects (BMI 30-39.9)</description>
          </group>
          <group group_id="O2">
            <title>Normal Weight Subjects</title>
            <description>Normal weight subjects (BMI 19-24.9)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a Maximum Follicle Diameter &gt; 13mm During the 3 Weeks of Follow-up</title>
          <description>Follicular development was minimal in both groups, with only five women achieving a maximum follicle diameter &gt; 13mm at any time during the 3 weeks of follow-up (3 normal weight and 2 obese women).</description>
          <population>17 participants in each group was planned a priori to have 80% power to identify a one standard deviation difference in the mean serum levels of the contraceptive hormones. We enrolled 40 women, 2 withdrew prior to the study cycle. We excluded one woman due to removal of the CVR during the study cycle leaving 18 normal weight and 19 obese women.</population>
          <units>Participant w/follicular diameter &gt;=13mm</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Endometrial Proliferation</title>
        <description>The mean endometrial proliferation from week 1, week 2 and week3</description>
        <time_frame>Transvaginal ultrasound measurements of endometrial proliferation will be completed over continuous ring use, an average of 3 weeks</time_frame>
        <population>17 participants in each group was planned a priori to have 80% power to identify a one standard deviation difference in the mean serum levels of the contraceptive hormones. We enrolled 40 women, 2 withdrew prior to the study cycle. We excluded one woman due to removal of the CVR during the study cycle leaving 18 normal weight and 19 obese women.</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Subjects</title>
            <description>Obese subjects (BMI 30-39.9)</description>
          </group>
          <group group_id="O2">
            <title>Normal Weight Subjects</title>
            <description>Normal weight subjects (BMI 19-24.9)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Endometrial Proliferation</title>
          <description>The mean endometrial proliferation from week 1, week 2 and week3</description>
          <population>17 participants in each group was planned a priori to have 80% power to identify a one standard deviation difference in the mean serum levels of the contraceptive hormones. We enrolled 40 women, 2 withdrew prior to the study cycle. We excluded one woman due to removal of the CVR during the study cycle leaving 18 normal weight and 19 obese women.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="1.8"/>
                    <measurement group_id="O2" value="3.9" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Obese Subjects</title>
          <description>Obese subjects (BMI 30-39.9)</description>
        </group>
        <group group_id="E2">
          <title>Normal Weight Subjects</title>
          <description>Normal weight subjects (BMI 19-24.9)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>fractured pelvis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>venous thrombosis</sub_title>
                <description>deep vein thrombosis of lower extremity during treatment. additional risk fact was long haul air travel</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carolyn Westhoff</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-4805</phone>
      <email>clw3@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

